This is actually GOOD NEWS for MSB as it is all about reproducible standards of production.
The standard may well be tough for MSB to reach but they are likely to reach it. Remember that our Japanese partner had production issues recently for instance.
MSB's competition on the other hand is unlikely to meet a tough standard set by the FDA..
Lots of shonky clinics have sprung up charging clients for stem cell cures and some times those clients receive no stem cells at all or anything of a constant standard quality and quantitative nature.
On the other hand insisting on more closely defining how the treatments mechanism works may well cause delays as more trials may be required but this is a grey area. When multi drug approaches are approved the exact mechanism is not required but it is merely assumed that the combo makes the difference. However big pharma would not be shy in trying things, even double standards, to slow things down.
MSB Price at posting:
$3.95 Sentiment: Buy Disclosure: Held
(20min delay)